Let’s #UniteforParkinsons?

EPDA CAMPAIGN TO CELEBRATE WORLD PARKINSON’S DAY – APRIL 11 EPDA (European Parkinson Disease Association) launched a campaign on World Parkinson’s Day and BIAL is united for Parkinson. 2017 marks 200 years since Parkinson’s was recognised as a health condition, so BIAL will be focused on this condition and on people living with Parkinson, as it is one of its research areas. #UniteforParkinsons


“ME AT MY BEST” - People with Parkinson's are "much more than their disease"

BIAL LAUNCHES INTERNATIONAL CAMPAIGN FOR WORLD PARKINSON'S DAY: APRIL 11 2017 Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush. This is how it feels to live with Parkinson’s, a real challenge for the 10 million of people diagnosed with Parkinson’s disease around the world.


BIAL is the third portuguese company which granted more patents in 2016

THE EUROPEAN PATENT OFFICE (EPO) GRANTS RECORD NUMBER OF EUROPEAN PATENTS LAST YEAR EPO published over 95 000 granted patents last year, 40% more than in 2015 and a new high mark in its history. In Portugal, BIAL is the third company which granted more patents last year. R&D is one of BIAL’s strategic area.


BIAL and Neurocrine Announce Exclusive North American Licensing Agreement for Opicapone

OPICAPONE APPROVED IN EUROPE IN JUNE 2016 BIAL and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America. Opicapone is a once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor (COMT inhibitor) that was approved in June 2016 by the European Commission as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations.


BIAL sells allergic immunotherapy business

BIAL has reached an agreement with the German company Roxall to sell its allergic immunotherapy business unit, known as BIAL Aristegui, dedicated to the development, production and commercialization of anti-allergic vaccines and diagnostic tests. This operation includes the commercial areas dedicated to allergology in Spain, Portugal and Italy, which represented 7% of BIAL's global turnover in 2016, as well as the R&D and industrial unit located in Bilbao, involving around 100 employees who will become integrated into Roxall.


Portugal’s Prime Minister and the Ministers of Health and Economy visited BIAL

The visit to the Research and Development Center, in Trofa, took place in the scope of an investment contract. BIAL has just signed an investment contract with the Portuguese Government of over €37 Mio, to be carried out until December 2018. The Prime Minister, António Costa, and the Ministers of Health and Economy attended the contract signature ceremony after visiting BIAL’s R&D Department.